黄龙咳喘胶囊治疗老年慢性支气管炎的疗效观察

发布时间：2018-03-13 13:12

本文选题：黄龙咳喘胶囊　切入点：慢性支气管炎　出处：《中药药理与临床》2017年05期 　论文类型：期刊论文

【摘要】：目的:黄龙咳喘胶囊治疗老年慢性支气管炎的临床疗效。方法:106例来自石河子大学医学院第一附属医院的老年慢性支气管炎患者(2015.8--2016.12)随机原则分为对照组和观察组,各53例。两组均接受常规治疗,观察组另外给予黄龙咳喘胶囊。结果:10天为一个疗程,治疗3个疗程后,观察组疗效(94.34%)明显高于对照组(77.36%)。经治疗,两组血清炎症水平、血液流变学指标均下降,血气指标得以改善,观察组hs-CRP、TNF-ɑ、IL-8水平分别低于对照组(9.73±2.42)mg/L比(12.91±2.86)mg/L、(0.51±0.29)ng/ml比(0.92±0.35)ng/ml、(0.60±0.34)ng/ml比(1.05±0.39)ng/ml,观察组Pa CO2和Pa O2均明显优于对照组(44.93±4.16)mm Hg比(50.27±4.47)mm Hg、(89.83±7.05)mm Hg比(81.27±6.72)mm Hg,观察组全血粘度高切、全血粘度低切、血浆粘度分别低于对照组(4.59±0.41)m Pa·s比(5.16±0.50)m Pa·s、(7.83±0.60)m Pa·s比(8.95±0.71)m Pa·s、(1.57±0.12)m Pa·s比(1.83±0.14)m Pa·s。对照组不良反应总发生率为11.32%,和观察组9.43%比,差异无统计学意义。结论:黄龙咳喘胶囊可作为老年慢性支气管炎的辅助用药,其可增加慢性支气管炎治疗效果,改善患者血气、血液流变学,降低炎症,且较为安全。
[Abstract]:Objective: to evaluate the clinical efficacy of Huanglong Kechuan capsule in the treatment of senile chronic bronchitis. Methods: one hundred and six elderly patients with chronic bronchitis from the first affiliated Hospital of Shihezi University Medical College were randomly divided into two groups: control group and observation group. There were 53 cases in each group. Both groups received routine treatment. The observation group was given Huanglong Kechuan capsule in addition. Results after 3 courses of treatment, the therapeutic effect of the observation group was 94.34) significantly higher than that of the control group (77.360.The level of serum inflammation in the two groups was significantly higher than that in the control group. The levels of hs-CRP TNF-tir IL-8 in the observation group were significantly lower than those in the control group (9.73 卤2.42 mg / L vs 12.91 卤2.86 mg / L vs 0.92 卤0.35 ng / ml vs 0.92 卤0.35 ng / ml vs 1.05 卤0.39 ng / ml, respectively). The CO2 and PaO2 in the observation group were significantly higher than those in the control group (44.93 卤4.16 mm Hg vs 50.27 卤4.47 mm Hg vs 81.27 卤6.72 mg / ml), and the blood viscosity of the observation group was significantly higher than that of the control group (44.93 卤4.16 mm Hg vs 50.27 卤4.47 mm / L vs 81.27 卤6.72 mm / ml). The whole blood viscosity was lower than that of the control group (4.59 卤0.41mPa 路s vs 5.16 卤0.50mPa 路s, 7.83 卤0.60mPa 路s vs 8.95 卤0.71mPa 路s vs 1.83 卤0.12mPa 路s vs 1.83 卤0.14mPa 路s, respectively). The total incidence of adverse reactions in the control group was 11.32, and that in the observation group was 9.43%. Conclusion: Huanglong Kechuan capsule can be used as an adjuvant drug for senile chronic bronchitis, which can increase the therapeutic effect of chronic bronchitis, improve blood gas, hemorheology, reduce inflammation, and is more safe.
【作者单位】：石河子大学医学院第一附属医院;
【分类号】：R259

【相似文献】